fda decision: roflumilast (arq-151) by arcutis biotherapeutics (on 2026-01-01)
Full Approval
fda decision: roflumilast (arq-151) by arcutis biotherapeutics (on 2026-01-01). Best Yes near 83¢ across 1 platform. Live cross-platform prices. Not financia…
Best Yes: 83¢ · Best No: 18¢ · 1 platform
- Kalshi: Yes 83¢ / No 18¢
LIVE
Full Approval
Volume
$24
$18 24h
Platforms
1
Cross-platform pricing
Resolution
Resolves Jul 1, 2026
~15 days left
Category
Economics
Yes
83¢
Kalshi
No
18¢
Kalshi
Opens on best-price platform
Compare & Trade
1 platform
Price History
Loading…
About This Market
If the FDA's decision on Roflumilast (ARQ-151) by Arcutis Biotherapeutics in June 2026 is Full Approval before Jul 1, 2026, the market resolves to Yes.
Market Details
ResolutionResolves Jul 1, 2026
Time Left15 days
Status● Active
CategoryEconomics
Yes
83¢
Kalshi
Payout 1.2x
No
18¢
Kalshi
Payout 5.6x
Opens on best-price platform
Compare & Trade
1 platformSign in to join the discussion
Sign In